bentracimab
AssetAlso called PB2452, bentracimab, MEDI-2452
Binds ticagrelor and its active metabolite to reverse antiplatelet activity.
- Stage
- Phase 3
- Modality
- Antibody
- Target
- Not known
- 7
- Indications
- 2
- Trials
- 3
- Developers
FDA orphan designation on Mar 18, 2025.
Indications
7Hemorrhage
Phase 3, Completed, NCT04286438, clinicaltrials.gov, Nov 14, 2026
Invasive procedure
Phase 3, Completed, NCT04286438, clinicaltrials.gov, Nov 14, 2026
Reversal of ticagrelor-induced antiplatelet effects in major bleeding or urgent surgery
Phase 3, SEC filing, Mar 11, 2021
4 more
In the full profile
- Owner and partners7
- Trials2
Every asset’s record: target, stage, trials and the evidence behind it.